Università Politecnica delle Marche AOU Ospedali Riuniti “Umberto I – GM Lancisi – G Salesi” Ancona - Italy The role of tumour Vascular Endothelial Growth.

Slides:

Advertisements

Similar presentations

Introduction Patients and Methods Results Conclusion Wnt signaling is essential for embryonic development, stem cells and tissue regeneration. Colorectal.

Advertisements

C. Lieu, H. Tran, Z. Jiang, M. Mao, M. Overman, C. Eng, J. Morris, L. Ellis, J. Heymach, and S. Kopetz Departments of Gastrointestinal Medical Oncology,

Northern England Strategic Clinical Network Conference Thyroid Sub-group Update Dr Sath Nag Consultant Endocrinologist Vice Chair, Thyroid NSSG South Tees.

Adjuvant therapy for renal cell carcinoma Dr.Mina Tajvidi oncologist.

Genetic Alterations of TP53 Gene in Brain Astrocytic Tumours Methodology Θ Eighty-three brain tumor biopsies were collected and used in this study. Thirty.

Efficacy and Safety of Single Agent Sunitinib in Treating Advanced Hepatocelluar Carcinoma Patients After Sorafenib Failure: A Prospective, Open-Label,

Na + /H + exchanger regulatory factor 1 (NHERF1) and angiogenesis in familial breast cancer A Mangia*, A Malfettone*, C Salvatore**, B Stea*, G Simone**

Prognose mittels Genexpression Prof. Martin H. Brutsche Kantonsspital St. Gallen-CH.

Mizutomo Azuma 1, Dongyun Yang 2, Marinella Carpanu 3, Ellen Hollywood 3, Michael Lue-Yat 3, Wu Zhang 1, Kathleen D. Danenberg 4, Peter V. Danenberg 5,

INCREASED EXPRESSION OF PROTEIN KINASE CK2  SUBUNIT IN HUMAN GASTRIC CARCINOMA Kai-Yuan Lin 1 and Yih-Huei Uen 1,2,3 1 Department of Medical Research,

Introduction Results Material and Methods Conclusions Genetic variants predict clinical outcome clinical outcome in patients (pts) with metastatic colorectal.

Role of CXCR4 and VEGF expression and metastatic locoregional lymphnodes in rectal carcinoma Tatangelo F.*, Avallone A.**, Delrio P.°, Scala S.§, Botti.

Fernando Cotait Maluf Diretor do Departamento de Oncologia Clínica Centro de Oncologia-Hospital São José Fernando Cotait Maluf Diretor.

Results 1 comparison for 5 systems containing the SNP at postion 1 to 5 of the up-stream probe  systems 2-5 work well, system 3 offers most stable & reliable.

S. K. Anderson 1, J. M. Lafky 1, X. W. Carrero 1, T. K. Kimlinger 1, T. M. Halling 1, S. Kumar 1, P. J. Flynn 2, H. M. Gross 3, K. A. Jaeckle 4, J. C.

Adjuvant systemic therapy in breast cancer Targeted therapies Update R. Paridaens Belgian Breast Meeting

Introduction Patients and Methods Results Conclusion Pericytes are a key component in the maturation of the VEGF driven tumor angiogenic process 1. Bevacizumab.

Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.

Introduction Patients and Methods Results Conclusion Table 1. Baseline characteristics of the 108 patients included in the biomarker analysis. Objectives.

IntroductionPatient baseline characteristics Conclusion The process of EGFR recycling is important mechanism of resistance of cetuximab in colorectal cancer.

Pharmacogenetic analysis in metastatic colorectal cancer (mCRC) patients treated with second-line irinotecan (IR)+/- cetuximab (CB): The EPIC experience.

Identification of localized rectal cancer (RC) patients (pts) who may NOT require preoperative (preop) chemoradiation (CRT). D. Roda 1, M. Frasson 2, E.

Adjuvant and Neoadjuvant Therapy in Non- Small Cell Lung Cancer Seminars in Oncology 2oo5;32 (suppl 2):S9-S15 Kyung Hee Medical Center Department of Thoracic.

HE-4 TRIAL Prospective phase II trial on the prognostic and predictive value of HE-4 regression during neoadjuvant chemotherapy for advanced ovarian, Fallopian.

COMPARING DISEASE OUTCOME OF WOMEN WITH HORMONE RECEPTOR NEGATIVE/HER2 POSITIVE (HR-/HER2+) OR TRIPLE NEGATIVE (TN) METASTATIC BREAST CANCER (MBC) RECEIVING.

第三章 Survivin siRNA nano particles are capable of inhibiting liver cancer cell growth both in vitro and in vivo Suoqin Tang,MD, Kuiyao Qu,MD, Yi Zhang,MD.

R2 김재민 / Prof. 정재헌 Journal conference 1.

Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy : A Korean multicenter.

Prof. Jae Heon, Jeong/R2 Cheol Hyun, Lee J of Clinical oncology, Vol 31 Number 4, Feb.1, 2013.

EGFR exon 20 insertion mutations

Angiotensin signalling in GBM: AT2R as a novel therapeutic target

miRNA-targets cross-talks: key players in glioblastoma multiforme

在使用Sorafenib治療肝細胞癌過程中患有

Alessandra Gennari, MD PhD

Comparison between Pathologic Characteristics of Her2 Negative and Positive Breast Cancer in a Single Cancer Center in Jordan DR Majdi A. Al Soudi, MD,

Uterine serous carcinoma is more aggressive than high-grade serous ovarian carcinoma: a retrospective study H. Nagano1, Y. Tachibana1, M. Kawakami1, M.

Pazopanib: the role in the treatment of mRCC

Presented By Michael Lee at 2016 ASCO Annual Meeting

Cancer Hospital & Institute, Chinese Academy of Medical Sciences

Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.

Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment Liver.

A REVIEW AND UPDATE ON THE ANTI-ANGIOGENIC AGENT, ABT-510

Presented By John Bartlett at 2017 ASCO Annual Meeting

Presented By Luca Malorni at 2017 ASCO Annual Meeting

OPTIMIZING TREATMENT FOR ADVANCED OVARIAN CANCER:

Marcelo Calil Instituto Brasileiro de Controle do Câncer

Clinical outcomes of advanced renal cell carcinoma following

ASSOCIATIONS BETWEEN ANXA11 RS C/T, BTNL2 RS G/A, HLA CLASS I AND II POLYMORPHISMS AND SARCOIDOSIS EVOLUTION Manuel Vaz1, Bruno Lima2, Natália.

Lo sviluppo clinico di nab-paclitaxel Discussant: Fabio Puglisi

A Paradigm Shift From One-Size-Fits-All to Tailor-Made Therapy for Metastatic Colorectal Cancer.

Figure 1 Current treatments for PNETs

Genetic variants of kinases suppressors of Ras (KSR)in KRAS-BRAF

Treating mRCC After Initial Antiangiogenic Therapy:

Reviewer: Dr. Sunil Verma Date posted: December 12th, 2011

Nat. Rev. Urol. doi: /nrurol

Baselga J et al. SABCS 2009;Abstract 45.

I.R.C.C.S. Policlinico San Matteo, Pavia

Targets for immunotherapy of liver cancer

Valencia, España SESION CONTROVERSIAS ¿Es necesario modificar el desarrollo clínico de los nuevos fármacos? COMENTARIOS Y DISCUSION Andres.

Published online September 20, 2017 by JAMA Surgery

Martin M et al. Proc SABCS 2012;Abstract S1-7.

Primary side of origin affects the outcome of mCRC patients treated with first-line FOLFIRI plus bevacizumab independently of BRAF status and mucinous.

(A) Survival time. (A) Survival time. All patients. (a) PFS since the start of EGFR-TKI (groups A, B and C). (b) OS since the start of EGFR-TKI (groups.

Treated with Neoadjuvant Therapy

KSR1 gene polymorphism in mCRC patients treated with first-line FOLFIRI and bevacizumab Marta Schirripa1, Fotios Loupakis1, Chiara Cremolini1, Dongyun.

Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular.

La nanomedicina in oncologia: presente e futuro

Surgical resection of metachronous liver metastases

Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.

The impact of body mass composition features on the outcome of HCC patients BACKGROUND Trends in hepatocellular carcinoma (HCC) have increased over recent.

Presentation transcript:

Università Politecnica delle Marche AOU Ospedali Riuniti “Umberto I – GM Lancisi – G Salesi” Ancona - Italy The role of tumour Vascular Endothelial Growth Factor (VEGF) and Vascular Endothelial Growth Factor Receptors (VEGFR) polymorphisms in the prediction of clinical outcome for advanced hepatocellular carcinoma receiving sorafenib. Luca Faloppi1, Mario Scartozzi1, Gianluca Svegliati Baroni2, Cristian Loretelli1, Samuele De Minicis2, Alessandra Mandolesi3, Simona Biagetti3, Maristella Bianconi1, Stefano Gemini2, Italo Bearzi3, Antonio Benedetti2, Stefano Cascinu1. 1) Clinica di Oncologia Medica; 2) Clinica di Gastroenterologia; 4) Anatomia Patologica. Background: Hepatocellular carcinoma (HCC) still represents a medical challenge in cancer therapy. In recent years the introduction of new targeted therapies has radically changed the approach to the disease and patients outcome. Currently the therapeutic stronghold is a TKIs directed against the VEGF family sorafenib. Polymorphisms of VEGF and its receptor genes are involved in regulating angiogenesis and lymphangiogenesis and thus in growth tumor control. The aim of our study is to evaluate the potential predictive and prognostic role of VEGF and VEGFR polymorphisms in determining the clinical outcome of HCC patients receiving sorafenib. Methods: 17 histologic samples (biopsies and surgical specimens) of HCC patients receiving sorafenib were tested for VEGF-A, VEGF-C and VEGFR-1,2,3 single nucleotide polymorphisms (SNPs). Patients time to progression (TTP) and overall survival (OS) were analysed. Results: VEGF-AI rs25648 C>T polymorphism was statistically significant in OS (15.0 months for C vs 9.4 months for T; p=0.025). VEGF-AII rs10434 G>A was statistically significant for TTP (4.1 months for G vs 1.2 months for A; p=0.0076) and OS (14.2 months for G vs 1.7 for A; p<0.0001). VEGF-CII rs7664413 C>T was significant in TTP (13.4 months for C vs 2.0 for T; p=0.0125) and OS (14.7 months for C vs 5.6 for T; p=0.0007). VEGR2-I rs1870377 A>T was significant in TTP (19.9 months for A vs 3.0 for T; p=0.0271) and OS (29.6 months for A vs 11.9 for T; p=0.0096). Conclusions: In our analysis patients with G polymorphism at rs10434, C polymorphism at rs7664413 and A polymorphism at rs1870377 have a better response (PFS and OS) during treatment with sorafenib. Patients with C polymorphism of rs7664413 and A polymorphism of rs1870377 show a favourable impact in this setting. Notably, VEGFR polymorphism result closely related to the treatment response and the specific signalling of sorafenib. Thus analysis of VEGF and its receptor genes polymorphisms represents a clinical tool to identify patients with favourable response to sorafenib presumably related to a more efficient control of tumor growth. Figure 1: Overall Survival VEGF A – RS25648 (CC > TT+CT) Figure 2: Progression Free Survival VEGF A – RS10431 (AA < GG+AG) Figure 3: Overall Survival VEGF A – RS10431 (AA < GG+AG) Figure 4: Progression Free Survival VEGF-CII RS7664413 (CC > TT+TC) Sample ID NCBI SNP Reference Reporter 1 Dye Reporter 1 Sequence Reporter 1 Frequence 2 Dye Reporter 2 Sequence Reporter 2 Frequence Design Strand Gene Symbol SNP Type VEGFA I rs25648 VIC C 0,836 FAM T 0,164 Reverse VEGFA SILENT MUTATION VEGFA II rs10434 A 0,371 G 0,629 Forward UTR 3 VEGFA III rs1570360 0,205 0,795 INTERGENIC/UNKNOWN VEGFA IV rs833061 0,422 0,578 VEGFA V rs699947 0,408 0,592 VEGFA VI rs2010963 0,431 0,569 UTR 5 VEGFA VII rs3025039 0,886 0,114 VEGF-C I rs4604006 0,678 0,322 VEGFC INTRON VEGF-C II rs7664413 0,792 0,208 VEGF-C III rs41367744 0,94 0,06 VEGFR-1 I rs664393 0,858 0,142 FLT1 VEGFR-1 II rs7993418 0,75 0,25 VEGFR-1 III rs35832528 0,492 0,508 MIS-SENSE MUTATION VEGFR-2 I rs1870377 0,275 0,725 KDR VEGFR-2 II rs2071559 0,483 0,517 VEGFR-2 III rs2305948 0,933 0,067 VEGFR-2 IV rs7667298 0,5 VEGFR-3 I rs307822 0,914 0,086 FLT4 VEGFR-3 II rs307805 0,108 0,892 VEGFR-3 III rs6877011 0,942 0,058 Figure 5: Overall Survival VEGF-CII RS7664413 (CC > TT+TC) Figure 6: Progression Free Survival VEGR2-I RS1870377 (TT< AA+AT) Correspondence to: Dr. Luca Faloppi lucafaloppi@libero.it Clinica di Oncologia Medica AOU “Ospedali Riuniti” Via Conca 71, 60020 Ancona Italy Scuola Specializzazione Oncologia Medica Università Politecnica delle Marche Via Tronto 10, 60020 Ancona Italy Figure 7: Overall Survival VEGR2-I RS1870377 (TT< AA+AT)